Literature DB >> 2242059

Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis.

J F Fries1, G Singh, L Lenert, D E Furst.   

Abstract

Levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) in patients with rheumatoid arthritis from 5 centers involved in the Arthritis, Rheumatism, and Aging Medical Information System were correlated with the use of specific antirheumatic medications. Elevated levels of SGOT and SGPT were most frequent in patients taking salicylates and methotrexate (MTX) and least frequent in patients taking hydroxychloroquine. The combination of MTX and salicylates greatly increased the frequency of abnormal liver enzyme values. In contrast, the addition of hydroxychloroquine to a regimen of either MTX or aspirin essentially eliminated the SGOT and SGPT abnormalities. Results from all 5 centers were consistent and remained so after adjustment for age, sex, and disease duration. Knowledge of these important drug interactions may permit continuation of MTX therapy in patients in whom the drug might otherwise be discontinued.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242059     DOI: 10.1002/art.1780331102

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

3.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

4.  Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study.

Authors:  Joshi Poorvashree; Dhaneshwar Suneela
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

Review 5.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 6.  Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?

Authors:  S Tariq; S M Tariq
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

7.  Long-term methotrexate in refractory rheumatoid arthritis; concurrent use of prednisone possibly improves drug-survival.

Authors:  P J Kerstens; A M Boerbooms; E P Brummelkamp; L B Van de Putte
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

8.  Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis.

Authors:  A S Williams; S G Jones; R M Goodfellow; N Amos; B D Williams
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 9.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 10.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.